The FDA Just Gave Abbott a Diabetes First. Is Its Beaten-Down Stock Ready to Wake Up?
Abbott just scored a regulatory first in diabetes care that no rival has matched, yet the stock sits well below where it traded a year ago. The real question is what it will actually take to close that gap.
On August 25, 2026, Abbott Laboratories (NYSE:ABT | ABT Price Prediction) received FDA De Novo authorization for the Libre Duo 10 Day, the first wearable cleared to continuously monitor glucose and detect rising ketone levels that can precede diabetic ketoacidosis.
De Novo is the pathway the FDA uses for novel low-to-moderate-risk devices that have no existing predicate. It marks a regulatory milestone that precedes any revenue impact.
The headline calls the stock beaten down, and the data mostly supports that framing. Abbott is down 11.29% over the past year and 7.25% year to date, though shares have rallied 9.2% over the past month to $114.10. The question is whether Libre Duo can push that recovery into a real re-rating.
What the FDA Cleared
Libre Duo is described by Abbott as “the world’s first dual glucose ketone wearable sensor.” Ketoacidosis can develop within hours, so an early warning built into the same patch that already tracks glucose is a genuine clinical distinction.
Abbott plans a U.S. launch later in 2026 for patients ages 2 and older, entering an ecosystem already used by more than 8 million people. Planned integrations with insulin pumps from Beta Bionics, Sequel, Insulet, Tandem and MiniMed are not yet live.
CE Mark came in May, and CEO Robert Ford said U.S. discussions were in “very, very advanced kind of final stages” on the Q2 call. The authorization confirms that timeline.
Is the Stock Actually Cheap Enough to Re-Rate
Abbott trades at a forward P/E of 21x against an analyst target of $120.20. That is a reasonable, though not distressed, multiple for a business raising full-year adjusted EPS guidance to $5.45 to $5.60.
Q2 CGM sales reached $2.188 billion, growing 9.5% comparable. Ford pushed back directly on the deceleration narrative: “I loved your characterization of only 9.5% on a $2 billion quarterly business.”
Meanwhile, Dexcom (NASDAQ:DXCM) shares are up 34.04% year to date, so the market has already rewarded the competitor. That gap sets up a catch-up trade if Libre Duo executes.
Where the Moat Actually Widens
The real leverage is reimbursement. Ford said reimbursement expansion “drastically accelerates” growth, and potential U.S. Type 2 coverage could reach around 10 million Medicare beneficiaries.
Ketone detection matters most for Type 1 patients and insulin-pump users, which is why the planned pump integrations are the commercial hinge. Until those go live, Libre Duo is a differentiator on the shelf rather than in the workflow.
My view is that this authorization is meaningful but insufficient on its own to warrant a re-rate of the stock. It becomes a catalyst when pump partners ship integrated systems, and CMS moves on broader Type 2 coverage, both events Ford flagged as possible in the fall.
Watch the Q3 report on adjusted EPS guidance of $1.38 to $1.46 and any reimbursement announcement. Those are the events that would convert first-mover status into durable earnings power.
Contact [email protected] for any questions or corrections.
Omor Ibne Ehsan is a writer at 24/7 Wall St. He is a self-taught investor with a focus on growth and cyclical stocks that have strong fundamentals, value, and long-term potential. He also has an interest in high-risk, high-reward investments such as cryptocurrencies and penny stocks.
